Search results
Results From The WOW.Com Content Network
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
The debut made Sandoz the largest new entrant to the Swiss stock exchange since 2019, when another Novartis spin-off, eyecare company Alcon, was valued at about 28 billion francs.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. [3] [4] Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals , focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies.
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. [4] Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until ...
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
By Geoffrey Smith. For premium support please call: 800-290-4726 more ways to reach us
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, [2] and Morges, Switzerland. [3] The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 [4] and Incyte Genomics, Inc. of Delaware. [5]
ZURICH/LONDON (Reuters) -Novartis plans to spin off its underperforming generics unit Sandoz to sharpen its focus on its patented prescription medicines, the Swiss group said on Thursday ...